Pharma & Bio
Lifestyle
PROTEINA CO., LTD. Benefits from AI-Driven New Drug Development… Ingenia Highlights the Technological Value of Its Global Phase 3 Trial [Bio Spotlight]
On the 23rd, the domestic pharmaceutical and life sciences sectors showed mixed trends. The life sciences sector rose 0.64%. Of the 92 stocks in the sector, 53 rose, 8 remained unchanged, and 31 fell,…
- 2026-09-29 07:31:02
- KIM JI-WAN
Technology
Graphy Chairman Outlines Ray Strategy and Relationship with MegaGen
Graphy has defined its relationship with MegaGen Implant, or MegaGen, primarily as a business partnership following its acquisition of management control of Ray.Although MegaGen holds a 7.69% stake in…
- 2026-09-29 06:01:04
- NA EUN-KYUNG
Technology
[Exclusive] Graphy Inc., Backed by Ray Co., Ltd.… CEO Shim Un-seop: “Business Cooperation with Megagen, Not a Battle for Control”
#Graphy Inc., which acquired management control of Ray Co., Ltd.(228670), announced that it has no plans to seek a seat on the board of Megagen Implant (hereinafter “Megagen”), the second-largest shar…
- 2026-09-29 06:01:02
- NA EUN-KYUNG
Technology
FDA Approval Is Just the Beginning… What Is HLB INC.’s Strategy to Break Into the Niche Market for Intrahepatic Bile Duct Cancer with ‘Ripictu’?
While HLB INC.(028300)has successfully obtained U.S. Food and Drug Administration (FDA) approval for “Ripicto” (active ingredient: lirapugratinib), a new drug for cholangiocarcinoma, analysts say that…
- 2026-09-28 13:46:03
- KIM SAE-MI
Technology
A Hurdle Even AeroSpace Technology of Korea, Inc. and Roche Couldn’t Clear… J2H Takes a Gamble on MASH with ‘Cortisol’
(Image: ChatGPT.)
While glucagon-like peptide-1 (GLP-1) drugs—treatments for obesity and metabolic disorders—have become the dominant trend as the biggest issue in the global pharmaceutical and bi…
- 2026-09-28 08:01:01
- KIM SUNG-JIN
Technology
"70% of Last Year's Revenue in Just Half a Year"... Will IVIM Technology, Inc. Be Able to Turn Things Around Next Year?
#IVIM Technology, Inc. is poised for a turnaround in its financial performance. In the first half of this year alone, the company achieved revenue approaching 70% of last year’s total, demonstrating r…
- 2026-09-27 08:21:02
- Kim Seung-kwon
Lifestyle
Mezzion Pharma Co., Ltd. Sets Separate “Price Tag” for New Kidney Disease Drug… Establishes U.S. Subsidiary with an Eye Toward M&A
Mezzion Pharma Co., Ltd.(140410)has established an additional U.S. subsidiary dedicated exclusively to the development of treatments for autosomal dominant polycystic kidney disease (ADPKD).According …
- 2026-09-26 11:01:02
- KIM JI-WAN
Technology
SK Bioscience Completes Phase 1 Trials for Its First mRNA Vaccine… Reasons for Caution in Moving to Phase 2
#SK Bioscience has completed the global Phase 1 clinical trial for “GBP560,” a Japanese encephalitis vaccine candidate currently under development using messenger ribonucleic acid (mRNA) technology. A…
- 2026-09-25 16:01:02
- KIM SUNG-JIN
Technology
“Beyond VEGF Inhibition to Vascular Normalization”… Ingenia and curacle co., ltd. Compete in TIE2 Therapy for Age-Related Macular Degeneration
The focus of research into treatments for wet age-related macular degeneration is broadening from preventing abnormal blood vessel formation to stabilizing the damaged blood vessels themselves. This a…
- 2026-09-25 11:01:01
- NA EUN-KYUNG
Technology
[Big Tech Enters New Drug Development] 2.9 Trillion vs. 16 Billion… Success of South Korean AI-Driven New Drugs Depends on “Stamina,” Not Algorithms
Isomorphic Labs, a spin-off from Google DeepMind, raised approximately 2.9 trillion won in a single funding round last May. During the same period, the Series B funding round for a leading South Korea…
- 2026-09-24 14:01:02
- Kim Seung-kwon
PHARM EDAILY
Shorts